Iorns E - Search Results

1

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.

Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A. Turner N, et al. Among authors: iorns e. Cancer Res. 2010 Mar 1;70(5):2085-94. doi: 10.1158/0008-5472.CAN-09-3746. Epub 2010 Feb 23. Cancer Res. 2010. PMID: 20179196 Free PMC article.

2

Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.

Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M, Tutt AN, Crook T, Lord CJ, Ashworth A. Iorns E, et al. Cancer Cell. 2008 Feb;13(2):91-104. doi: 10.1016/j.ccr.2008.01.001. Cancer Cell. 2008. PMID: 18242510 Free article.

3

Dissecting resistance to endocrine therapy in breast cancer.

Lord CJ, Iorns E, Ashworth A. Lord CJ, et al. Among authors: iorns e. Cell Cycle. 2008 Jul 1;7(13):1895-8. doi: 10.4161/cc.7.13.6118. Epub 2008 Apr 16. Cell Cycle. 2008. PMID: 18604164

4

Utilizing RNA interference to enhance cancer drug discovery.

Iorns E, Lord CJ, Turner N, Ashworth A. Iorns E, et al. Nat Rev Drug Discov. 2007 Jul;6(7):556-68. doi: 10.1038/nrd2355. Nat Rev Drug Discov. 2007. PMID: 17599085 Review.

5

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor.

Turner NC, Lord CJ, Iorns E, Brough R, Swift S, Elliott R, Rayter S, Tutt AN, Ashworth A. Turner NC, et al. Among authors: iorns e. EMBO J. 2008 May 7;27(9):1368-77. doi: 10.1038/emboj.2008.61. Epub 2008 Apr 3. EMBO J. 2008. PMID: 18388863 Free PMC article.

6

Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization.

Iorns E, Lord CJ, Ashworth A. Iorns E, et al. Biochem J. 2009 Jan 1;417(1):361-70. doi: 10.1042/BJ20081682. Biochem J. 2009. PMID: 18976239

7

Integrated functional, gene expression and genomic analysis for the identification of cancer targets.

Iorns E, Lord CJ, Grigoriadis A, McDonald S, Fenwick K, Mackay A, Mein CA, Natrajan R, Savage K, Tamber N, Reis-Filho JS, Turner NC, Ashworth A. Iorns E, et al. PLoS One. 2009;4(4):e5120. doi: 10.1371/journal.pone.0005120. Epub 2009 Apr 9. PLoS One. 2009. PMID: 19357772 Free PMC article.

8

CRK7 modifies the MAPK pathway and influences the response to endocrine therapy.

Iorns E, Martens-de Kemp SR, Lord CJ, Ashworth A. Iorns E, et al. Carcinogenesis. 2009 Oct;30(10):1696-701. doi: 10.1093/carcin/bgp187. Epub 2009 Aug 3. Carcinogenesis. 2009. PMID: 19651820

9

Infiltrating S100A8+ myeloid cells promote metastatic spread of human breast cancer and predict poor clinical outcome.

Drews-Elger K, Iorns E, Dias A, Miller P, Ward TM, Dean S, Clarke J, Campion-Flora A, Rodrigues DN, Reis-Filho JS, Rae JM, Thomas D, Berry D, El-Ashry D, Lippman ME. Drews-Elger K, et al. Among authors: iorns e. Breast Cancer Res Treat. 2014 Nov;148(1):41-59. doi: 10.1007/s10549-014-3122-4. Epub 2014 Oct 1. Breast Cancer Res Treat. 2014. PMID: 25270120

10

Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor.

Iorns E, Ward TM, Dean S, Jegg A, Thomas D, Murugaesu N, Sims D, Mitsopoulos C, Fenwick K, Kozarewa I, Naceur-Lombarelli C, Zvelebil M, Isacke CM, Lord CJ, Ashworth A, Hnatyszyn HJ, Pegram M, Lippman M. Iorns E, et al. Breast Cancer Res Treat. 2012 Aug;135(1):79-91. doi: 10.1007/s10549-012-2068-7. Epub 2012 Apr 26. Breast Cancer Res Treat. 2012. PMID: 22535017

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

69 results

Search Page